安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Personalis | Transforming the Active Management of Cancer
Personalis is revolutionizing cancer care with combined expertise in advanced testing, cancer genomics, and data science Partner with us to unlock the potential of personalized treatments, drive groundbreaking innovations and better patient outcomes
- Personalis, Inc. - LinkedIn
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing We aim to drive a new paradigm for cancer management, guiding care from biopsy
- PERSONALIS, INC. - NPI 1003232158 - Clinical Medical Laboratory in . . .
This page provides the complete NPI Profile along with additional information for Personalis, Inc , a provider established in Fremont, California operating as a Clinical Medical Laboratory
- Personalis, Inc. in Fremont, CA 94555 - 855-436. . . - Chamber of Commerce
Personalis, Inc located at 6600 Dumbarton Cir, Fremont, CA 94555 - reviews, ratings, hours, phone number, directions, and more
- Personalis | (650) 752-1300 | Fremont, California - AllBiz
Personalis, Inc is a growing cancer genomics company that is revolutionizing the development of next-generation therapies by offering comprehensive molecular data on each patient's cancer and immune response
- Personalis (PSNL) Company Profile Description - Stock Analysis
Company profile for Personalis, Inc (PSNL) stock, with a description, list of executives, contact details and other key facts
- Personalis, Inc. (PSNL) Company Profile Facts - Yahoo Finance
See the company profile for Personalis, Inc (PSNL) including business summary, industry sector information, number of employees, business summary, corporate governance, key executives and
- Personalis Reports Fourth Quarter and Full Year 2025 Results . . . - BioSpace
FREMONT, Calif -- (BUSINESS WIRE)--Personalis, Inc (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the fourth quarter and full year ended December 31, 2025 and recent business highlights and provided financial guidance for the full year 2026
|
|
|